Work

KRAS G12C Inhibitors on the Horizon

Year: 2019

Type: article

Abstract: Among the different known mutations, KRAS G12C (glycine 12 to cysteine) is quite prevalent and has been considered druggable.

Source: Future Medicinal Chemistry

DOI: 10.4155/fmc-2018-0304

Authors: Ali Cagir, Asfar S Azmi

Institutions: Izmir Institute of Technology, Wayne State University, The Barbara Ann Karmanos Cancer Institute

Language: English

Topic: Protein Kinase Regulation and GTPase Signaling

Subfield: Molecular Biology

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

Open Access status: bronze

Funders: National Institutes of Health, National Cancer Institute

Awards: Clinical Translation of Nuclear Export Inhibitor in Metastatic Pancreatic Cancer, G3208868322

OpenAlex ID: W2947517655

FWCI: 0.43

Cites: 11

Cited by: 8

Related to: 10